JPRN-UMIN000007941已完成2 期
Phase ll trial of TS-1 + CDDP + Trastuzumab (SPT) - 3 weekly schedule in HER2-positive advanced gastric cancer without measurable metastatic lesion (HERBIS-1B) (OGSG 1202) - HER2-Based Strategy in Gastric Cancer (HERBIS-1B) (OGSG 1202)
Osaka Gastrointestinal cancer chemotherapy Study Group (OGSG)0 个研究点目标入组 15 人开始时间: 2012年5月14日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
Fifteen patients were enrolled. The median overall survival was 14.4 months. The 1- and 3-year overall survival rates were 66.7 % and 26.7 %, respectively.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients who are contraindicated to S-1, CDDP, and Trastuzumab 2. Women in pregnancy, at risk of pregnancy, hoping to become pregnant. Men who want their partners to become pregnant 3. Patient with active infection 4. Patients have Active hepatitis type B. 5. Serious illness or medical conditions as defined below, a) Patient with a previous history of congestive heart failure b) Hi-risk uncontrolled arrhythmias c) Unstable angina requiring medication d) Patient with a previous history of myocardial infarction e) Severe heart valve disease f) Patient with a previous history of transmural infarct g) Uncontrolled hypertension 6. Serious complication as followings, a) Interstitial pneumonia b) Pulmonary fibrosis c) Heart failure d) Renal failure e) Hepatic failure f) Uncontrolled diabetes mellitus 7. Patients with resting dyspnea 8. Patients with fresh bleeding from gastric cancer and/or the digestive tract 9. Patients with diarrhea (4 or more times per day or watery diarrhea). 10. Second primary malignancy (except adequately treated basal cell carcinoma treated more than 5 years ago without recurrence) 11. Patients who are received systemic continuous administration of flucytosine, phenytoin or warfarin 12. Patients who are received systemic administration of corticosteroid 13. Any patients judged by the investigator to be unfit to participate in the study
研究者
相似试验
招募中
2 期
Clinical trial of TS-1 + CDDP + Trastuzumab-3 weekly cycle in HER2-positive advanced gastric cancerHER2 positive advanced gastric cancerJPRN-UMIN000009865Dokkyo Medical University8
已完成
2 期
Phase ll trial of TS-1 + CDDP + Trastuzumab(SPT)-3 weekly schedule in HER2-positive advanced gastric cancer(HERBIS-1) (OGSG 1101)Advanced Gastric CancerJPRN-UMIN000005739Osaka Gastrointestinal cancer chemotherapy Study Group (OGSG)56
已完成
1 期
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)Advanced Breast CancerNCT01976169University of Texas Southwestern Medical Center29
已完成
3 期
Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric CancerGastric CancerNCT00150670Taiho Pharmaceutical Co., Ltd.300
已完成
2 期
A Phase II Study of Trastuzumab plus S-1 in Patients with Advanced or Recurrent HER2 positive Breast CancerBreast cancerJPRN-UMIN000001408Gunma Breast Clinical Conference Study Group(GBCCSG)30